- TRUE HUMAN™
- CORPORATE STRATEGY
XBiotech was founded in 2005 based on the premise that pharmacologically relevant antibodies were present in humans that could be cloned and used as therapeutics. These human derived antibodies (True Human™) are expected to offer the best possible safety and tolerability.
The potential for using human-sourced antibodies was recognized as a largely untapped resource. Thus commercialization of True Human™ therapeutics was deemed to represent breakthrough, first-in-class products in the rapidly growing business of therapeutic antibodies.
XBiotech was founded to assemble the core technology and expertise to establish a discovery program for True Human™ antibodies. The Company’s lead product, MABp1, is a True Human™ Antibody that targets a master regulator of chronic inflammation—interleukin-1 alpha (IL-1α). MABp1 clinical data so far suggests extraordinary clinical value; as well, these data support the original premise of True Human™ antibody safety and tolerability.
XBiotech is incorporated in Canada, the United States, Switzerland and Japan, while all operating facilities reside in Austin, Texas. Research and development work continues for a number of different antibody targets—with ongoing screening of human blood for new candidate therapeutics. However, much of the Company’s resources are now devoted to commercializing its lead product candidate MABp1.
The Company has established an in-house clinical regulatory program, which is enabled by in-house cGMP drug manufacturing, product formulation, and a fill-finish operation to supply all clinical drug product needs. Dynamic drug production and clinical trial management capabilities have been at the heart of XBiotech’s rapid value creation effort and aggressive commercialization plan.
The Company has pioneered technology solutions to manufacture its drug product using a minimal infrastructure concept. A result has been the development of a manufacturing process that dramatically reduces capital requirements and operating complexity.
© 2012 XBiotech USA, Inc. | All Rights Reserved